Troubles rose again for Cipla Ltd as the US Food and Drug Administration slapped a form 483 with six inspectional observations on the drugmaker's manufacturing facility at Patalganga in Maharashtra.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback